Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Mirati Therapeutics (NQ: MRTX )

37.54 -0.17 (-0.45%)
Streaming Delayed Price Updated: 10:03 AM EDT, Mar 30, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Mirati Therapeutics

< Previous 1 2 3 4 5 6 Next >
Coinbase, MercadoLibre And Some Other Big Stocks Recording Gains On Thursday
U.S. stocks closed mixed on Thursday following the release of weekly jobless claims data. Here is the list of some big stocks moving higher in the previous session. 
Via Benzinga
Mirati Therapeutics: Q2 Earnings Insights
Mirati Therapeutics (NASDAQ:MRTX) reported its Q2 earnings results on Wednesday, August 3, 2022 at 04:01 PM. Here's what investors need to know about the announcement. 
Via Benzinga
Biotech Daily: Merck's Two Combo Cancer Trials Miss Main Goal, Approval For Sinovac's COVID-19 Shot For Youngest Kids, Alnylam Aces Protein Disorder Trial
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
10 Analysts Have This to Say About Mirati Therapeutics
Analysts have provided the following ratings for Mirati Therapeutics (NASDAQ:MRTX) within the last quarter: 
Via Benzinga
Mirati Therapeutics Posts Adagrasib Data In Lung Cancer Patients With CNS Metastases
 
Via Benzinga
Amgen Touts Early Lumakras Combo Data In KRAS Cancer Settings
BMO Capital Markets says that while Amgen Inc's (NASDAQ: AMGN) Lumakras (sotorasib) + PD1i data was delayed to the August 7 presentation, it did get data on the Lumakras + SHP2 inhibitor combination.  
Via Benzinga
Biotech ETF Tops in June: 5 Stocks That Outperform
Although most of the stocks in BBC’s portfolio have delivered strong returns this year so far, a few have gained more than 45%. 
Via Talk Markets
Bear Market Rally Lifts HealthCare Stocks Off Bottom
Clearly we are in a biotech bear market with both diagnostics and vaccine revenues stalled. If gene editing stocks cannot offer breakthrough clinical news then stick with large cap biopharma. 
Via Talk Markets
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Good morning, investor! We're back with a breakdown of the biggest pre-market stock movers for Tuesday to get the day started! 
Via InvestorPlace
Expert Ratings for Mirati Therapeutics
Within the last quarter, Mirati Therapeutics (NASDAQ:MRTX) has observed the following analyst ratings: 
Via Benzinga
Here's What Cramer Has To Say About Zuora, Johnson Controls International And More
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Zuora Inc (NYSE: ZUO) is losing money. "It does not fit our criteria of what you should own," he added. 
Via Benzinga
79 Biggest Movers From Yesterday
Gainers AeroClean Technologies, Inc. (NASDAQ: AERC) gained 154.7% to settle at $12.10 on Tuesday on continued strength after the FDA granted clearance for the company's pūrgo technology, classifying it... 
Via Benzinga
Mid-Afternoon Market Update: Dow Rises 100 Points; Kiromic BioPharma Shares Spike Higher
U.S. stocks turned higher toward the end of trading, with the Dow Jones gaining more than 100 points on Tuesday. 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
 
Via Benzinga
Mid-Day Market Update: Nasdaq Turns Higher; REV Group Shares Plunge
U.S. stocks pared losses, with the Nasdaq Composite turning higher midway through trading on Tuesday. 
Via Benzinga
38 Stocks Moving In Tuesday's Mid-Day Session
Gainers Kiromic BioPharma, Inc. (NASDAQ: KRBP) gained 70% to $0.4900 after the company entered a sponsored research agreement under which in vivo preclinical data will be generated from Kiromic's Gamma... 
Via Benzinga
The Surprising Way Mirati Therapeutics Is Angling To Rival Amgen — And Could Succeed
Mirati Therapeutics said a combination using its KRAS drug appeared promising. 
Via Investor's Business Daily
Mid-Morning Market Update: Markets Open Lower; United Natural Foods Tops Q3 Views
U.S. stocks traded lower this morning, with the Dow Jones dropping more than 100 points on Tuesday. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 7, 2022
Upgrades 
Via Benzinga
69 Biggest Movers From Friday
Gainers Turning Point Therapeutics, Inc. (NASDAQ: TPTX) shares climbed 118.4% to close at $74.59 on Friday after Bristol Myers Squibb announced it will acquire Turning Point Therapeutics for $76 per... 
Via Benzinga
Stocks Pacing for Weekly Losses Despite Strong Jobs Data
Wall Street is unpacking a strong jobs report this afternoon, though stocks are sliding as economists weigh the U.S. Federal Reserve's plans to continue hiking interest rates. 
Via Talk Markets
40 Stocks Moving In Friday's Mid-Day Session
Gainers Turning Point Therapeutics, Inc. (NASDAQ: TPTX) shares jumped 115.8% to $73.72 after Bristol Myers Squibb announced it will acquire Turning Point Therapeutics for $76 per share. 
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
During Friday's session, 59 stocks hit new 52-week lows. 
Via Benzinga
70 Biggest Movers From Friday
Gainers Avadel Pharmaceuticals plc (NASDAQ: AVDL) shares climbed 133.6% to close at $2.50 on Friday. Avadel Pharmaceuticals shares dipped 68% on Thursday after announcing new FDA request for... 
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers 
Via Benzinga
Mirati Therapeutics Plunges As Its Hopes To Take On Amgen In Lung Cancer Crash
Mirati is unlikely to carve out share with a drug that didn't differentiate, analysts say. 
Via Investor's Business Daily
Mid-Morning Market Update: Markets Open Higher; US Goods Trade Deficit Narrows In April
U.S. stocks traded higher this morning, with the Dow Jones gaining more than 100 points on Friday. 
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
 
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 20, 2022
Upgrades 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.